RBC Capital maintains Pacira BioSciences at Sector Perform
RBC Capital reiterated its “Sector Perform” rating on Pacira BioSciences, per a Benzinga ratings-action roundup.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
RBC Capital maintains Sector Perform on Pacira BioSciences, $36.50 target
RBC Capital maintained a Sector Perform rating on Pacira BioSciences and kept its $36.50 price target, roughly in line with the Oct. 8 close of $36.39.